Author + information
- Wilko Spiering,
- Jan Van der Heyden,
- Abraham Kroon,
- Anton van den Meiracker,
- Chandan Devireddy,
- Malcolm Foster III,
- Magdi Ghali,
- Farrell Mendelsohn,
- Hannes Reuter,
- John Reilly and
- Mark Bates
Background: To evaluate the safety and performance of a novel endovascular carotid barostimulation device to decrease blood pressure (BP) in patients with resistant hypertension.
Methods: 9 centers have participated in the first-in-man assessment of the MobiusHD device, a nitinol self-expanding implant designed to increase carotid sinus arterial wall strain and enhance baroreceptor sensitivity. Patients with resistant hypertension, office systolic BP (SBP) ≥160 mmHg, without obstructive carotid disease were eligible. Safety information along with changes in BP were collected during 1.5 year follow-up.
Results: 40 patients, mean age 53 years, have been enrolled and received a MobiusHD implant. Mean pretreatment office BP was 182/107 (±17/15) mmHg with a mean of 4.4 prescribed antihypertensives [daily defined dose (DDD): 7.0]. During follow-up no unanticipated adverse device effects and 9 serious adverse events were reported as possibly related to the procedure or device: puncture site bleeding due to closure device complication (n=1), symptomatic hypotension (n=6) and symptomatic hypertension (n=2). All events were managed successfully and resolved. At 180 days, 34 of the 37 (91.9%) patients had a reduction in office SBP ≥10 mmHg and/or 24-hr SBP ≥5 mmHg. 18 of these 37 (48.6%) patients had a reduction in DDD of antihypertensive medications.
Conclusions: Implanting the MobiusHD device in patients with resistant hypertension appears to be safe and shows promising results in lowering BP.
Poster Hall, Hall C
Friday, March 17, 2017, 3:45 p.m.-4:30 p.m.
Session Title: Novel Mechanical Devices for the Treatment and Assessment of Hypertension
Abstract Category: 33. Prevention: Hypertension
Presentation Number: 1146-033
- 2017 American College of Cardiology Foundation